The US FDA has approved Eli Lily’s oral therapy Reyvow (lasmiditan) for the acute treatment of adults with migraine with or without aura, with Lilly noting that this is ‘the first and only FDA-approved medicine in a new class of serotonin (5-HT)1F receptor agonists’.
